10:25 AM EST - Bausch Health Companies Inc. : Announced topline results from a Phase 2 study evaluating an investigative soluble solid dispersion formulation of immediate release rifaximin in combination therapy with the current standard of care therapy, lactulose, for the treatment of Overt Hepatic Encephalopathy. Bausch Health Companies Inc.
shares T.BHC are trading up $1.16 at $22.76.
